Mary Kubota
Primary Care · Temecula, CANPI 1689840464
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,256 of the $7,468 with a category attached, or 83.8%. It is spread thinly across 31 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,730 and has fallen 70.4% since, to $809 in 2025. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $25.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$646
- Boehringer Ingelheim$633
- Amarin Pharma, Inc.$380
- plus $2K from 25 others
What the payments were for
- Consulting fees$80011%
- Speaking & faculty fees$290%
- Travel & lodging$3334%
- Food & beverage$6,25684%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $1,539 |
| AbbVie(2 entities) | 53 | $1,186 |
| AstraZeneca | 43 | $1,124 |
| Novo Nordisk | 41 | $646 |
| Boehringer Ingelheim | 27 | $633 |
| Amarin Pharma, Inc. | 23 | $380 |
| Amgen | 12 | $264 |
| GSK | 11 | $248 |
| Lilly USA, LLC | 9 | $179 |
| Pfizer | 7 | $155 |
| Johnson & Johnson | 7 | $147 |
| Kowa Pharmaceuticals America, Inc. | 6 | $132 |
| Currax Pharmaceuticals LLC | 7 | $121 |
| Exact Sciences | 4 | $75 |
| Hologic Sales And Service, LLC | 3 | $73 |
| Biohaven Pharmaceuticals, Inc. | 3 | $68 |
| Medicure Pharma Inc. | 2 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Bayer | 2 | $50 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Abbott | 2 | $39 |
| Merck | 2 | $33 |
| Seqirus USA Inc | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Alk-abello, Inc | 1 | $23 |
| Edwards Lifesciences | 1 | $22 |
| Medtronic | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,378
- Ozempic$125
- FARXIGA$120
- BREZTRI$104
- AIRSUPRA$104
How this compares
$7,468 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $80,621 |
| EliquisApixaban | 64 | $50,922 |
| RybelsusSemaglutide | 26 | $38,914 |
| FarxigaDapagliflozin Propanediol | 22 | $33,477 |
| JardianceEmpagliflozin | 14 | $22,928 |
| LinzessLinaclotide | 16 | $18,443 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $15,467 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,125 |
| Icosapent Ethyl | 16 | $4,786 |
| PremarinEstrogens, Conjugated | 11 | $4,392 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $4,308 |
| Atorvastatin Calcium | 332 | $3,275 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $2,854 |
| Nebivolol Hcl | 28 | $1,848 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $646 | $119,53585 claims |
| PfizerEliquis, Premarin | $155 | $55,31475 claims |
| AstraZenecaFarxiga | $1,124 | $33,47722 claims |
| Boehringer IngelheimJardiance | $633 | $22,92814 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $248 | $20,59133 claims |
| AbbVieLinzess, Synthroid | $1,186 | $19,36838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in Temecula
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.